Skip to contentpdufa.bio

ateganosine THIO-104

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ateganosine THIO-104 is a MAIA Biotechnology, Inc. program in third-line advanced NSCLC. Its next catalyst is a Readout in Q4 2027.

MAIA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: third-line advanced NSCLC. Sponsor: MAIA Biotechnology, Inc. (MAIA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027MAIA

Questions

When is ateganosine THIO-104's next FDA decision or readout?

The next tracked catalyst for ateganosine THIO-104 is a Readout in Q4 2027.

What happened at ateganosine THIO-104's most recent FDA decision?

No FDA decision for ateganosine THIO-104 is in our archive yet.

What is ateganosine THIO-104 used for?

In our records ateganosine THIO-104 is under review or in development for third-line advanced NSCLC.

Who makes ateganosine THIO-104?

MAIA Biotechnology, Inc. (MAIA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.